Original Research Article

Need of the hour: pharmacovigilance study of SGLT-2 inhibitors

Sapna Pradhan, Tejus A.*, Mrinalini Koley, A. G. Mathur

Department of Pharmacology, Army College of Medical Sciences, New Delhi, India

Received: 03 March 2019
Accepted: 20 March 2019

*Correspondence:
Dr. Tejus A.,
E-mail: dmntejus@gmail.com

ABSTRACT

Background: Diabetes mellitus represents a global pandemic. Various pharmacotherapy and non-pharmacotherapy measures are advocated for its control. The latest in the pharmacotherapy are Sodium Glucose Transporter -2 (SGLT-2) inhibitors, widely used. Many studies suggest adverse effects related to SGLT-2 inhibitors, evidence still not conclusive and few data from India. Hence this study was planned.

Methods: Cross-sectional study over a period of 02 months, recorded demographic details and history of various adverse drug reactions reported with the use of SGLT-2 inhibitors.

Results: Majority of the study participants were females (58%) and belonged to the age group of 40-70 yrs. Urinary tract infections (UTI) and genital infections was more seen in the users of dapagliflozin, followed by empagliflozin and canagliflozin.

Conclusions: SGLT-2 Inhibitors offer a unique therapeutic approach to the management of Diabetes Mellitus. Further evaluation of the safety profile and the risk-benefit analysis is the need of the hour.

Keywords: Diabetes mellitus, Genital infections, Pharmacovigilance, Safety profile, SGLT-2 Inhibitors, UTI

INTRODUCTION

Diabetes mellitus is a chronic metabolic disorder with association of elevated blood glucose levels resulting from either insulin deficiency or action. It represents a global pandemic with the number of affected individuals getting quadrupled over the last three decades. An estimate suggests that more than 415 million are affected by diabetes globally with numbers expected to cross 640 million by 2040. It is projected that globally 1 in every 11 adults are diabetic, with 90% of affected individuals are of type 2 diabetes mellitus. Initially considered to be a disease of affluent countries, latest report by International Diabetic Federation (IDF) suggests that China (109.6 million) and India (69.2 million) represent the countries with largest number of diabetics.

In India the overall prevalence stands at 7.3%, with a higher prevalence in urban areas compared to rural areas and a higher prevalence in states with high per-capita GDP. In collaboration with genetic predisposition, unhealthy dietary habits and lifestyle contribute to an individual susceptibility to diabetes. The long term complications of uncontrolled hyperglycaemia predominantly involve the vasculature contributing to microvascular and macrovascular changes affecting various organs. It is estimated that globally around 193 million diabetics escape the radar of diagnosis contributing to the long term complications.

Management of diabetes includes lifestyle modifications along with pharmacotherapy. The approved pharmacotherapy includes various formulations of insulin (short acting, intermediate acting and long acting), biguanides, thiazolidinediones, sulfonylureas, meglitidine
analogues, dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium glucose co-transporter-2 (SGLT-2) inhibitors and alpha-glucosidase inhibitors.\textsuperscript{7,8} Biguanide like metformin act by inhibiting the mitochondrial respiratory chain complex leading to an increase in ratio of adenosine monophosphate (AMP) to adenosine di-phosphate (ADP). This further activates AMP-activated protein kinase (AMPK) which ultimately inhibits gluconeogenesis. Metformin also inhibits glycerol-3-phosphate dehydrogenase in mitochondria inhibiting gluconeogenesis.\textsuperscript{9,9}

Sulfonylureas like glimepiride, glipizide and glyburide acts by binding to ATP-dependent sulfonylurea receptor leading to stimulation of insulin secretion from pancreatic beta cells.\textsuperscript{10} Thiazolidinediones (pioglitazone) act as agonist at peroxisomal proliferative activated receptor-alpha (PPAR-\alpha) and leads to insulin sensitizing effect.\textsuperscript{11} Meglitinide analogues (repaglinide and nateglinide) also are insulin secretagogues, but are shorter and faster acting.\textsuperscript{12} DPP-4 inhibitors prevent the breakdown of glucagon like peptide-1 (GLP-1) secreted by intestinal tract, which inhibits glucagon release, gluconeogenesis and gastric emptying gets delayed.\textsuperscript{13}

There has been a better understanding of kidney’s role in glucose homeostasis leading to development of SGLT-2 inhibitors. SGLT-2 inhibitors decrease renal glucose reabsorption, excretion and subsequent reductions in plasma glucose which results in enhanced urinary glucose and glycosylated haemoglobin concentrations.\textsuperscript{14} The novelty of action gives SGLT-2 inhibitors the added advantage of combining with other glucose-lowering agents.\textsuperscript{14} SGLT-2 inhibitors are known to reduce body weight, blood pressure and serum uric acid. Three drugs, namely dapagliflozin, empagliflozin and canagliflozin have been recently introduced in India.\textsuperscript{15,16}

SGLT-2 inhibitors although considered to be well tolerated, potential adverse effects of urinary tract infections and mycotic genital tract infections exists due to continuous presence of urinary glucose.\textsuperscript{17} By increasing renal tubular reabsorption of phosphate and parathyroid hormone secretion SGLT-2 inhibitors increase FGF-23 secretion from osteocytes which causes bone resorption leading to fractures. A SGLT2 inhibitors cause a modest osmotic diuresis, there may be a risk of hypotension, hypovolemia, and dehydration.\textsuperscript{18}

Although few studies have been conducted on the adverse effects noted with this new class of anti-diabetic drugs, there is a paucity of data on the effects associated with the use of these agents in Indian population. Hence this study was conducted to report the adverse effects associated with the use of SGLT-2 inhibitors.

Aim and objective was to study the adverse events associated with the use of SGLT-2 inhibitors (empagliflozin, dapagliflozin and canagliflozin) in Indian patients of type 2 diabetes mellitus.

\section*{METHODS}

It was a cross-sectional study conducted in the endocrinology department of a 1000 bedded tertiary care hospital. After obtaining approval from institutional ethical committee the study was conducted on 100 randomly selected diabetic patients aged >18 years, of either sex, providing informed consent and receiving one of the SGLT-2 inhibitors as treatment. Those patients declining the informed consent and pregnant women were excluded from the study. The study was conducted over a period of 02 months in the months of May and June 2018.

The demographic profile (age, gender and locality) of those participating in the study was recorded. The duration from the onset of diabetes and their treatment regimen was recorded. Any history of any adverse reactions during the use of SGLT-2 inhibitors (Urinary tract infections; genital infections; symptoms of hypoglycaemia-dizziness, fainting; increased urine frequency/ volume; symptoms suggestive of DVT-Pain in the legs, redness, swelling; history of fractures, stroke and any other adverse effects other than above) was recorded. All the data were tabulated and analyzed. The causality assessment of adverse reactions reported was done using WHO-UMC criteria.

\section*{RESULTS}

Majority of the study participants were females (58\%) and belonged to the age group of 40-70 yrs (Table 1). Out of 100 individuals recruited into the study majority of them were prescribed canagliflozin (54\%) followed by empagliflozin (33\%) and dapagliflozin (13\%). The users of dapagliflozin reported more history of UTI (76.92\%) in comparison to empagliflozin (39.4\%) and canagliflozin (31.48\%). Similar to UTI, genital infections were more with dapagliflozin (76.92\%). The users of empagliflozin did not report any symptoms of DVT, whereas it was reported by users of canagliflozin (18.52\%) and dapagliflozin (23.08\%) (Table 2, Figure 1).

\begin{table}[H]
\centering
\caption{Table 1: Demographic characteristics.}
\begin{tabular}{|c|c|}
\hline
\textbf{Demographic characteristics} & \textbf{Males} & \textbf{Females} \\
\hline
\textbf{Gender} & 42 & 58 \\
\hline
\textbf{Age (In yrs)} & & \\
1-10 & Nil & Nil \\
11-20 & Nil & Nil \\
21-30 & Nil & Nil \\
31-40 & 12 & \\
41-50 & 21 & \\
51-60 & 25 & \\
61-70 & 29 & \\
71-80 & 13 & \\
81-90 & 00 & \\
91-100 & 00 & \\
\hline
\end{tabular}
\end{table}
Table 2: History of adverse reactions reported by users of SGLT-2 inhibitors.

<table>
<thead>
<tr>
<th>H/O adverse reactions on SGLT-2 inhibitors</th>
<th>Canagliflozin (54)</th>
<th>Empagliflozin (33)</th>
<th>Dapagliflozin (13)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Reported</td>
<td>Not reported</td>
<td>Reported</td>
</tr>
<tr>
<td>Urinary tract infections</td>
<td>17 (31.48%)</td>
<td>37 (68.52%)</td>
<td>13 (39.4%)</td>
</tr>
<tr>
<td>Genital infections</td>
<td>17 (31.48%)</td>
<td>37 (74.08%)</td>
<td>14 (42.42%)</td>
</tr>
<tr>
<td>Symptoms of hypoglycemia: dizziness, fainting</td>
<td>27 (50%)</td>
<td>27 (50%)</td>
<td>13 (39.4%)</td>
</tr>
<tr>
<td>Increased urine frequency/volume</td>
<td>04 (7.41%)</td>
<td>50 (92.59%)</td>
<td>10 (30.31%)</td>
</tr>
<tr>
<td>Symptoms suggestive of DVT (Pain in the legs, redness, swelling)</td>
<td>10 (18.52%)</td>
<td>44 (81.48%)</td>
<td>Nil</td>
</tr>
<tr>
<td>History of fractures</td>
<td>04 (7.41%)</td>
<td>50 (92.59%)</td>
<td>Nil</td>
</tr>
<tr>
<td>History of stroke</td>
<td>Nil</td>
<td>54 (100%)</td>
<td>1 (3.03%)</td>
</tr>
</tbody>
</table>

**Figure 1: Summary of adverse reactions reported by users of SGLT-2 inhibitors.**

History of fractures was reported by only the users of canagliflozin (7.41%). There was only one participant who reported a history of stroke 06 months ago. Amongst the other adverse effects reported include nausea (9%), vomiting (3%), dry mouth (2%), anorexia (2%) and hair loss (1%) (Table 2).

According to WHO-UMC scale, the causality assessment of adverse drug reactions (ADRs) reported by users of SGLT-2 inhibitors revealed, 95% ADRs as possible and the remaining 5% ADRs as unclassifiable (Figure 2).

**Figure 2: Adverse drug reactions.**

**DISCUSSION**

Pharmacotherapy of diabetes is an ever evolving arena with only insulin, metformin and pioglitazone ruling the zone initially, but off late new groups of drugs DPP-4 inhibitors (gliptins) and SGLT-2 inhibitors are often used as add on drugs. Hence, this study was planned to assess the prevalence of adverse effects in users of SGLT-2 inhibitors.

In our study the users of dapagliflozin reported highest incidence of UTI (76.92%) followed by canagliflozin and empagliflozin. The results were in line with meta-analysis of randomized controlled trials (RCTs) on SGLT-2 inhibitors safety and efficacy by Liu XY et al. The meta-analysis clearly highlighted the increased risk of UTIs in users of SGLT-2 inhibitors in comparison to placebo.19 However; this was refuted by Ueda P et al, in their nationwide registry based cohort study assessing the use of SGLT-2 inhibitors and risk of serious adverse events.
They reported that SGLT-2 inhibitors in comparison to GLP-1 receptor agonists were not associated risk of serious UTIs.19 Liu et al, in their systemic review and meta-analysis of randomized controlled trials on the effects of SGLT-2 inhibitors on UTI and genital infections demonstrated no significant difference between SGLT-2 inhibitor group and control.20

The reported incidence of genital infections was again highest amongst the users of dapagliflozin (76.92%) followed by empagliflozin and canagliflozin. Liu J et al, in their systemic review and meta-analysis of randomized controlled trials have clearly highlighted the risk of genital infections with the use of SGLT-2 inhibitors in comparison to controls.20 In this study, the symptoms of DVT was minimally seen with most reported by users of dapagliflozin (23.08%) followed by canagliflozin (18.52%). The users of empagliflozin did not report any symptoms of DVT. Ueda et al, in their nationwide registry have brought similar results and demonstrated that there was no increased risk of venous thromboembolism in users of SGLT-2 inhibitors in comparison to GLP-1 agonists.21

The history of bone fractures was minimal (7.41%), with all the reported cases were users of canagliflozin. The results of our study commensurate with the nationwide registry by Ueda et al, who brought that there is no increased risk of bone fractures amongst SGLT-2 inhibitor users in comparison to GLP-1 agonists.21

The existing literature comparing the effects of individual SGLT-2 inhibitors various ADRs is conflicting and most RCTs compare individual SGLT-2 inhibitors with placebo. Hence, our study provides a basic template for comparing the various ADRs amongst the SGLT-2 inhibitors. The drawbacks of our study are it is not a randomized trial, just a cross-sectional study and was based on the memory of the users, hence subjected to bias. Hence, it is highly essential to conduct an RCT in Indian population comparing each SGLT-2 inhibitor for their ADRs and also in comparison in placebo.

CONCLUSION

SGLT-2 Inhibitors offer a unique therapeutic approach to the management of diabetes mellitus. Additional nonglycemic advantaged includes weight loss and blood pressure reduction, which may confer additional health benefits. Due to limited current post marketing data on the use of these agents, further evaluation of the safety profile and the risk-benefit analysis is the need of the hour. The present study shall provide additional information of the magnitude and clinical importance of the adverse events associated with their use. This will further elucidate the future therapeutic role of SGLT-2 inhibitors in the already rich armamentarium for the management of diabetes mellitus.

Funding: No funding sources

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES
